AG
ANIK icon

Aperio Group’s Anika Therapeutics ANIK Stock Holding History

Aperio Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,380
Closed -$279K – 2337
2019
Q4 		$279K Sell
5,380
-159
-3% -$9.24K ﹤0.01% 2094
2019
Q3 		$304K Buy
5,539
+484
+10% +$24.9K ﹤0.01% 2012
2019
Q2 		$205K Buy
+5,055
New +$184K ﹤0.01% 2166

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aperio Group's ANIK Position: Q1 2020 in Review

Aperio Group sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 5,380 shares — an estimated $279K sold.

Aperio Group first reported a position in ANIK in Q2 2019 and held it in 3 quarters. The position peaked at $304K in Q3 2019. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • Aperio Group reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Aperio Group sold 5,380 Anika Therapeutics shares in Q1 2020, an estimated $279K.
  • Aperio Group first reported a position in Anika Therapeutics in Q2 2019 and held it in 3 quarters.
  • Aperio Group's Anika Therapeutics position peaked at $304K in Q3 2019.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Aperio Group's 13F filing for Q1 2020, filed 5 May 2020.